MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ajh.23676

Медицинская библиотека · American journal of hematology · 2014

JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events.

Alvarez-Larrán Alberto, Bellosillo Beatriz, Pereira Arturo, Kerguelen Ana, Hernández-Boluda Juan Carlos, Martínez-Avilés Luz, Fernández-Rodríguez Concepción, Gómez Montse, Lombardía Luis, Angona Anna, Ancochea Agueda, Senín Alicia, Longarón Raquel, Navarro Blanca, Collado María, Besses Carlos

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

The JAK2V617F allele burden has been identified as a risk factor for vascular events and myelofibrotic transformation in polycythemia vera (PV) and essential thrombocythemia (ET). However, all previous studies have evaluated a single time point JAK2V617F measurement. Therefore, the frequency and the clinical significance of changes in the JAK2V617F mutant load occurring during the disease evolution remain unknown. In the present study, JAK2V617F monitoring was performed during the follow-up of 347 patients (PV = 163, ET = 184). According to their JAK2V617F evolutionary patterns, patients were stratified as stable < 50% (n = 261), stable ≥50% (n = 52), progressive increase (n = 24) and unexplained decrease (n = 10). After a 2,453 person-years follow-up, a total of 59 thrombotic events, 16 major hemorrhages, and 27 cases of myelofibrotic transformations were registered. At multivariate analyses, patients with a persistently high (≥50%) or unsteady JAK2V617F load during follow-up had an increased risk of myelofibrotic transformation (Incidence rate ratio [IRR]: 20.7, 95% CI: 6.5-65.4; P < 0.001) and a trend for a higher incidence of thrombosis (IRR: 1.7, 1-3.3; P = 0.05) than patients with a stable allele burden below 50%. In conclusion, JAK2V617F monitoring could be useful in patients with PV and ET for predicting disease's complications, especially myelofibrotic transformation.

Для цитирования: Alvarez-Larrán Alberto, Bellosillo Beatriz, Pereira Arturo, Kerguelen Ana, Hernández-Boluda Juan Carlos, Martínez-Avilés Luz, Fernández-Rodríguez Concepción, Gómez Montse, Lombardía Luis, Angona Anna, Ancochea Agueda, Senín Alicia, Longarón Raquel, Navarro Blanca, Collado María, Besses Carlos. JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events.. American journal of hematology. 2014. DOI: 10.1002/ajh.23676.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.